Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

NCT00922272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia and Predominant Negative Symptoms

Interventions

DRUG: SPD489 (lisdexamfetamine dimesylate)
DRUG: Placebo matching SPD489 (lisdexamfetamine dimesylate)

Sponsor

Shire